CFRX ContraFect Corp

9,717

$0.0632

$0.0034

(5.69%)

Today

Watchers	9,717
52-Wk Low	$0.043
52-Wk High	$13.02

Market Cap	$676,115.00
Volume (M)	6,656.00
52-Wk High	$13.02
52-Wk Low	$0.043

Fundamentals

ContraFect files to sell $15M of common stock, Class E warrantsThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Share to Feed

ContraFect files to sell 7.03M shares of common stock for holdersThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyGlobe Newswire • about 2 months ago

CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trialYONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq...

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentGlobe Newswire • 3 months ago

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370Globe Newswire • 3 months ago

YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023Globe Newswire • 3 months ago

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect (CFRX) Receives a Buy from Maxim GroupTipRanks Financial Blog • 4 months ago

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX Research Report), with a price target... In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ContraFect (CFRX &#8211...

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobe Newswire • 4 months ago

YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionGlobe Newswire • 5 months ago

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening...